ADNI
-
A4 study, ADNI, Alzheimer’s disease, amyloid PET, blood biomarker, Brain, calibration, cognition, machine learning, negative predictive value, Neurodegenerative Diseases, p-tau217, plasma biomarkersAlzheimer’s Blood Biomarker Models Lose Rule-Out Power Across Cohorts
A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still…
-
ADNI, Alzheimer’s disease, ANA-GNN, artificial-intelligence, Brain, clinical decision support, cognition, dementia diagnosis, graph neural network, hippocampus, machine learning, mild cognitive impairment, Neurodegenerative Diseases, neuroimaging, neuroscience, posterior cingulate cortex, structural MRIAlzheimer’s AI MRI Diagnosis: ANA-GNN Reaches 85.23% Accuracy in ADNI
A 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural…
-
ADNI, Alzheimer’s disease, amyloid, APOE, APOE-e4, blood biomarker, Brain, cognition, donanemab, Drugs, genetics, lecanemab, longitudinal cohort, mild cognitive impairment, Neurodegenerative Diseases, neuroscience, p-tau217, preclinical ADPlasma p-tau217 Blood Test Predicts Alzheimer’s Risk 1.5x Stronger in APOE-e4
Until recently, Alzheimer’s pathology could only be confirmed in living patients via…
